Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Durante, Cosimo; Haddy, Nadia; Baudin, Éric; Leboulleux, Sophie; Hartl, Dana M.; Travagli, J. P.; Caillou, Bernard; Ricard, M.; Lumbroso, J.; Vathaire, Florent de; Schlumberger, Martin

doi:10.1210/jc.2005-2838

Cited by 1,440 publications

(1,148 citation statements)

References 23 publications

Supporting

Mentioning

1,034

Contrasting

Unclassified

Order By: Relevance

“…28 -30 However, recurrence develops in 20% to 40% of patients, and with the rare occurrence of distance metastasis or extensive local invasion, the prognosis is significantly poorer. 28,31 Understanding the specific mechanisms involved in the deregulation of cell growth and cell death in thyroid cancer is critical for developing new treatments.…”

Section: Discussionmentioning

confidence: 99%

XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth

Shiozaki

Lodyga

Bai

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

Adaptor proteins with multimodular structures can participate in the regulation of various cellular functions. We have cloned a novel adaptor protein, XB130, which binds the p85␣ subunit of phosphatidyl inositol 3-kinase and subsequently mediates signaling through RET/ PTC in TPC-1 thyroid cancer cells. In the present study, we sought to determine the role of XB130 in the tumorigenesis in vivo and in related molecular mechanisms. In WRO thyroid cancer cells, knockdown of XB130 using small interfering RNA inhibited G 1 -S phase progression, induced spontaneous apoptosis, and enhanced intrinsic and extrinsic apoptotic stimulus-induced cell death. Growth of tumors in nude mice formed from XB130 shRNA stably transfected WRO cells were significantly reduced, with decreased cell proliferation and increased apoptosis. Microarray analysis identified 246 genes significantly changed in XB130 shRNA transfected cells. Among them, 57 genes are related to cell proliferation or survival, including many transcription regulators. Ingenuity Pathway Analysis showed that the topranked disease related to XB130 is cancer, and the top molecular and cellular functions are cellular growth and proliferation and cell cycle. A human thyroid tissue microarray study identified expression of XB130 in normal thyroid tissue as well as in human thyroid carcinomas. These observations suggest that the expression of XB130 in these cancer cells may affect cell proliferation and survival by controlling the expression of multiple genes, especially transcription regulators.

show abstract

Section: Discussionmentioning

confidence: 99%

XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth

Shiozaki

Lodyga

Bai

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…In adults, it has been established that RAI therapy leads to a reduced risk of recurrence and mortality in DTC with postsurgical residual disease [44,45].In a meta-analysis, RAI benefit was demonstrated in adults with stage III and IV disease but not in stage I [46]. However this issue has not been well addressed in children.…”

Section: Treatment -Radioactive Iodine (Rai) Therapymentioning

confidence: 99%

Pediatric Thyroid Cancers: An Indian Perspective

Chaukar

Vaidya

2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Pediatric thyroid cancer is a rare entity accounting for less than 5% of all thyroid cancers. This intriguing disease is characterized by advanced presentation, coupled with frequent lymph nodal metastases and often pulmonary metastases. It perhaps exhibits a distinct biology and behaviour, because in spite of its aggressiveness, survival is extremely good. This mandates meticulous treatment decisions that are well executed, because the complications of therapy in patients with good survival may spell prolonged morbidity. Being an unusual disease, it is unlikely that level I evidence guiding the management will come forth. There have been controversies regarding management, and the current consensus comes from large prospective studies. There have been only a few studies from India detailing pediatric thyroid cancers. In the current discussion, we review the existing evidence about pediatric thyroid cancers, and try to have an Indian perspective at the problem.

show abstract

“…These patients can experience 10-year survival rates as high as 85% (2,3). Unfortunately, local or distant metastases can occur, and 25%-66% of patients with locally advanced or metastatic disease will become refractory to treatment with radioiodine (RAI) (4,5). Patients with advanced RAI-refractory DTC are rare, representing < 5% of patients with clinical thyroid cancer.…”

Section: Ifferentiated Thyroid Cancer (Dtc) Accountsmentioning

confidence: 99%

“…At least 131 I refractory disease should be defined as the presence of a lesion that does not uptake 131 I detected at imaging, or clinical evidence that 131 I is no longer beneficial despite visible uptake or, for example, cumulative activity > 600 mCi (4,10,11). In the latter case, tumor progression should also be confirmed by imaging performed every 6 to 14 months according to Response Evaluation Criteria in Solid Tumors (12).…”

Section: Ifferentiated Thyroid Cancer (Dtc) Accountsmentioning

confidence: 99%

Response to sorafenib treatment in advanced metastatic thyroid cancer

Pitoia

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma. Subjects and methods: Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months). Results: Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%. Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death. Conclusion: These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled. Arq Bras Endocrinol Metab. 2014;58(1):37-41 Keywords Metastasis; sorafenib; thyroid; cancer RESUMO Objetivo: Investigar a eficácia do sorafenibe no carcinoma de tireoide metastático progressivo e refratário à iodoterapia. Sujeitos e métodos: Estudo observacional do efeito do sorafenibe off-label administrado 400 mg duas vezes ao dia. A duração da terapia foi de 12 ± 3 meses (variação de 6-16 meses). Resultados: Oito pacientes foram incluídos (sete com variante papilífera e um com variante insular). Os oito pacientes que preencheram os critérios do estudo receberam o sorafenibe 400 mg por via oral duas vezes por dia até progressão da doença ou toxicidade inaceitável. Um paciente apresentou uma resposta parcial com regressão tumoral da lesão alvo de 35% seis meses após o início do tratamento; cinco pacientes apresentaram doença estável e dois pacientes progrediram e morreram. A tireoglobulina diminuiu 50% ± 23% em 4 semanas em todos os pacientes. Eventos adversos: um paciente teve insuficiência cardíaca e morreu por morte súbita cinco meses após a retirada do sorafenibe. Conclusão: Esses dados sugerem um possível papel para sorafenibe para o tratamento do CDT metastático progressivo. Arq Bras Endocrinol Metab. 2014;58(1):37-41Descritores

show abstract

Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Cited by 1,440 publications

References 23 publications

XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth

XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth

Pediatric Thyroid Cancers: An Indian Perspective

Response to sorafenib treatment in advanced metastatic thyroid cancer

Contact Info

Product

Resources

About